Critical Insights: Ewing Sarcoma Oncology Cases & Prognosis

Patient Presentation & History

A 15-year-old Caucasian male presented with a 4-month history of insidious onset right thigh pain and progressive swelling. Initially, the pain was intermittent, dull, and exacerbated by physical activity, but it gradually worsened to a constant, throbbing ache present even at rest and during the night, interfering with sleep. He reported developing a noticeable swelling in the mid-thigh region approximately 6 weeks prior to presentation, which had progressively increased in size. He denied any specific trauma or injury to the limb.

Associated symptoms included low-grade fevers (Tmax 38.2°C) occurring intermittently over the past month, unintentional weight loss of approximately 3 kg over the same period, and generalized fatigue. There was no history of chronic illness, previous surgeries, or significant past medical history. Family history was negative for bone tumors or genetic syndromes. He was an active high school athlete, participating in soccer. Social history was unremarkable.

Clinical Examination

Inspection

On inspection, a fusiform swelling was evident in the mid-diaphyseal region of the right thigh, measuring approximately 15 x 10 cm. The overlying skin appeared taut and erythematous, with prominent superficial venous engorgement. No open wounds, ecchymosis, or obvious neurological deformities were noted. The patient exhibited an antalgic gait, favoring the right lower limb, and appeared pale and somewhat cachectic.

Palpation

Palpation revealed a firm, fixed, and exquisitely tender mass occupying the middle third of the right femur. The mass was warm to the touch, and its margins were ill-defined, blending into the surrounding musculature. There was no palpable fluctuation. Regional lymph nodes (inguinal) were not enlarged. Distal pulses (femoral, popliteal, dorsalis pedis, posterior tibial) were all palpable and symmetrical.

Range of Motion

Range of motion of the right hip and knee joints was assessed. Hip flexion was restricted to 90 degrees (normal 120-130), abduction to 20 degrees (normal 40-50), and internal rotation to 15 degrees (normal 30-45) due to pain and guarding, particularly with end-range movements. Knee flexion was full (0-140 degrees), but extension was met with mild pain. Ankle and foot range of motion were unrestricted.

Neurological/Vascular Assessment

Neurological examination of the right lower extremity revealed intact motor strength (5/5 MRC scale) in all major muscle groups distal to the knee. Sensory examination was normal to light touch and pinprick in all dermatomes (L2-S1). Deep tendon reflexes (patellar, Achilles) were symmetrical and 2+. No pathological reflexes were elicited. Capillary refill in the toes was brisk (<2 seconds). There was no evidence of neurovascular compromise despite the significant size of the mass.

Imaging & Diagnostics

Initial Radiographs

Initial plain radiographs of the right femur (AP and lateral views) revealed a large, destructive, permeative lytic lesion involving the mid-diaphysis of the femur. Classic "onion skin" lamellated periosteal reaction was prominent, indicating an aggressive process. Significant cortical destruction and an associated large soft tissue mass were evident, extending well beyond the bone margins. No definite sclerotic margins were present.

Computed Tomography (CT) Scan

A CT scan of the right femur with contrast was performed for better delineation of bony destruction, cortical breach, and intramedullary and extraosseous soft tissue involvement. It confirmed a large, expansile, destructive lesion with extensive cortical erosion and a significant soft tissue component, measuring approximately 12 x 8 x 10 cm. The CT scan provided excellent detail regarding the extent of marrow involvement and the relationship of the tumor to critical neurovascular structures, demonstrating close proximity to the femoral vessels and sciatic nerve, but no direct invasion at this stage. Additionally, a CT scan of the chest, abdomen, and pelvis was performed for metastatic staging, which revealed a solitary, 1.5 cm pulmonary nodule in the right lower lobe, suspicious for metastasis.

Magnetic Resonance Imaging (MRI)

MRI of the entire right femur (including proximal and distal joints) with gadolinium contrast was performed for local staging. The MRI demonstrated a diffuse, high signal intensity lesion on T2-weighted images and STIR sequences, with heterogeneous enhancement after gadolinium administration, indicative of a highly vascularized malignant process. It precisely defined the intraosseous extent, revealing skip lesions approximately 4 cm proximal to the main tumor in the intramedullary canal, and confirmed extensive extraosseous soft tissue extension, encasing, but not invading, the femoral neurovascular bundle. The MRI was critical for planning surgical margins, assessing the reactive zone, and identifying viable tumor for biopsy.

Positron Emission Tomography-CT (PET-CT)

A whole-body 18F-FDG PET-CT scan was performed to assess metabolic activity of the primary tumor and to detect occult distant metastatic disease. It showed intense FDG avidity in the primary femoral lesion (SUVmax 18.5) and confirmed the pulmonary nodule as metabolically active (SUVmax 4.2). No other sites of increased metabolic activity suggestive of metastatic disease were identified.

Bone Scintigraphy

Technetium-99m bone scintigraphy revealed intense uptake at the primary femoral lesion and mild uptake in the right lower lobe pulmonary nodule (consistent with findings on PET-CT), further supporting a multifocal process.

Biopsy

An image-guided core needle biopsy of the femoral lesion was performed by an orthopedic oncologist, carefully planning the biopsy tract to be excised en bloc with the definitive tumor resection. Multiple cores were obtained. Histopathological examination revealed a highly malignant, small round blue cell tumor. Immunohistochemistry was positive for CD99 (MIC2) and showed negativity for leukocyte common antigen (LCA), desmin, and S100 protein. Molecular studies confirmed the presence of the characteristic EWS-FLI1 fusion transcript [t(11;22)(q24;q12)] , definitively establishing the diagnosis of Ewing Sarcoma.

Laboratory Studies

Full blood count showed mild anemia (Hb 10.8 g/dL). Erythrocyte sedimentation rate (ESR) was elevated at 78 mm/hr, and C-reactive protein (CRP) was 45 mg/L. Lactate dehydrogenase (LDH) was also elevated at 350 U/L (normal < 250 U/L), which is a known poor prognostic indicator in Ewing Sarcoma. Renal and liver function tests were within normal limits.

Differential Diagnosis

The clinical presentation, particularly in an adolescent with localized pain, swelling, constitutional symptoms, and aggressive radiographic findings, necessitated a broad differential diagnosis.

Surgical Decision Making & Classification

Given the confirmed diagnosis of Ewing Sarcoma with metastatic disease to the lung, the case was discussed extensively within a multidisciplinary sarcoma tumor board, involving orthopedic oncology, pediatric oncology, radiation oncology, diagnostic radiology, and pathology.

Principles of Management for Ewing Sarcoma:
Ewing Sarcoma is a highly aggressive malignancy and is considered a systemic disease at presentation, even if no distant metastases are detectable by conventional imaging. Therefore, multimodality therapy is the cornerstone of treatment, always involving systemic chemotherapy.

The primary goals of treatment were:
1. Eradicate micrometastatic disease and control macroscopic metastatic disease.
2. Achieve local disease control with definitive surgery and/or radiation therapy.
3. Preserve limb function where feasible.

Enneking Staging System (MSTS Staging):
Based on the imaging and biopsy findings, the patient was classified as:
* Grade (G): G2 (High-grade malignancy, Ewing Sarcoma is inherently G2).
* Site (T): T2 (Extracompartmental, due to extensive soft tissue extension beyond the reactive pseudocapsule and involvement of the femoral diaphyseal musculature).
* Metastasis (M): M1 (Distant metastasis confirmed with a solitary lung nodule).
This placed the patient in Stage III (G2, T2, M1) according to the Enneking system, indicating an aggressive, metastatic disease requiring comprehensive systemic and local therapy.

Surgical Decision-Making:
The decision for surgical intervention was made after initial neoadjuvant chemotherapy, which is standard for all Ewing Sarcomas.
* Rationale for Operative Management: En bloc resection with wide surgical margins offers the best chance for local disease control, superior to radiation therapy alone for resectable tumors. It also provides the opportunity for definitive histological assessment of tumor response to chemotherapy (tumor necrosis rate, a key prognostic indicator).
* Neoadjuvant Chemotherapy: The patient initiated a standard regimen of neoadjuvant chemotherapy (e.g., VDC/IE - Vincristine, Doxorubicin, Cyclophosphamide alternating with Ifosfamide, Etoposide) for 12 weeks. The goals were to:
* Treat micrometastatic disease.
* Shrink the primary tumor, facilitating a safer resection with wider margins.
* Assess tumor response (clinical, radiological, pathological after resection).
* Potentially sterilize the lung metastasis (though the lung nodule would also be addressed via wedge resection).

Post-neoadjuvant chemotherapy imaging (repeat MRI) showed a significant reduction in tumor size (approximately 50% decrease in volume) and improved delineation of the reactive zone. The lung nodule also showed a modest decrease in size. This favorable response to chemotherapy made limb salvage a viable option.

Considerations for Limb Salvage vs. Amputation:
* Favorable factors for limb salvage: Good response to chemotherapy, resectability with wide margins without sacrificing critical neurovascular structures, patient and family preference.
* Unfavorable factors (leading to amputation): Extensive neurovascular involvement requiring sacrifice of major vessels/nerves, diffuse skip lesions, pathological fracture precluding adequate margins, poor response to chemotherapy, uncontrolled infection, or patient preference.
In this case, despite close proximity to the femoral vessels and sciatic nerve, pre-operative planning indicated that a wide margin could be achieved with careful dissection, preserving neurovascular structures. The patient was also young and highly motivated for limb preservation.

Reconstruction Options Considered for a Mid-Diaphyseal Femoral Defect:
1. Extensible Endoprosthesis: Ideal for growing children/adolescents, allowing for limb lengthening without repeat major surgery. However, the patient was 15, nearing skeletal maturity.
2. Non-extensible Modular Endoprosthesis: Standard for large segmental resections in skeletally mature patients. Offers immediate stability and weight-bearing potential. Risks include aseptic loosening, infection, and mechanical failure.
3. Allograft Reconstruction: Biological option, aiming for eventual bony incorporation. Risks include non-union, fracture, infection, and slower rehabilitation.
4. Combined Allograft-Prosthesis Composite: Utilizes an allograft for biological integration with a prosthetic component for articulation.
5. Vascularized Fibular Autograft: Excellent for smaller defects, especially in children, due to growth potential and resistance to infection. Not ideal for a large diaphyseal femoral defect in a load-bearing area.

Given the large defect and the patient's age (nearing skeletal maturity), a modular endoprosthetic reconstruction was deemed the most appropriate choice to achieve immediate stability, allow for early mobilization, and provide a durable reconstructive solution.

Surgical Technique / Intervention

The surgical procedure involved two main components: definitive resection of the primary femoral tumor with endoprosthetic reconstruction, and a concomitant wedge resection of the pulmonary metastasis.

Pre-operative Planning

Extensive pre-operative planning was undertaken using 3D reconstructions from CT and MRI scans. The planned osteotomy levels were determined to achieve at least a 2 cm gross wide margin from the maximal intraosseous tumor extent, as defined by MRI, encompassing the entire biopsy tract. The type and size of the modular endoprosthesis were templated based on the length of the resected segment and patient anatomy.

Patient Positioning

The patient was positioned supine on a radiolucent operating table. The right lower limb was prepped and draped freely to allow full range of motion. A pneumatic tourniquet was available but not inflated initially, as meticulous hemostasis was paramount due to the high vascularity of the tumor bed and the need for clear dissection planes around neurovascular structures.

Surgical Approach

A standard extensile lateral approach to the right femur was utilized. A longitudinal incision was made, centered over the palpable mass, extending proximally and distally to allow for adequate exposure. The prior biopsy incision and tract were included within the margins of the skin ellipse, which was excised en bloc with the underlying tumor.
Subcutaneous tissues were incised, and muscle layers were carefully separated. The vastus lateralis was incised longitudinally, and the muscle attachments to the femur overlying the tumor were sharply dissected from proximal to distal. Dissection proceeded carefully through the reactive zone, outside the pseudocapsule of the tumor. The femoral neurovascular bundle (femoral artery, vein, and nerve) was meticulously identified and protected anteriorly and medially. The sciatic nerve was identified posteriorly and protected.

Resection Technique

En bloc resection of the involved mid-diaphyseal segment of the right femur was performed.
1. Proximal Osteotomy: A Gigli saw was used to perform a sharp transverse osteotomy proximally, ensuring a minimum of 2 cm clear margin from the visible tumor on bone and within the marrow. Intraoperative frozen section analysis of the bone margins was performed to confirm tumor-free margins.
2. Distal Osteotomy: A similar technique was applied distally, again ensuring a 2 cm clear margin.
3. Soft Tissue Dissection: After the osteotomies were complete, the remaining soft tissue attachments to the resected segment were sharply divided, ensuring the entire tumor, reactive zone, and biopsy tract were removed in one piece.
4. Specimen Orientation: The resected segment was carefully oriented and sent to pathology for definitive margin assessment and evaluation of tumor necrosis following neoadjuvant chemotherapy.

Reconstruction with Modular Endoprosthesis

Following successful en bloc resection and confirmation of negative margins:
1. Femoral Canal Preparation: The proximal and distal femoral canals were reamed to accept the modular prosthetic components. Careful reaming ensured proper fit and alignment.
2. Trial Reduction: Trial components of the modular endoprosthesis (proximal stem, diaphyseal segment, distal stem, and articulating components) were inserted to confirm correct length, rotational alignment, and stability.
3. Definitive Implantation: The definitive modular endoprosthesis was then assembled. Both the proximal and distal stems were cemented into the femoral canals using polymethylmethacrylate (PMMA) bone cement, ensuring robust fixation. The diaphyseal component connected the two stems, restoring the length and mechanical axis of the femur.
4. Soft Tissue Reattachment: The surrounding musculature (vastus lateralis, adductor magnus, rectus femoris, vastus intermedius) was meticulously reattached to the prosthetic components or to adjacent soft tissues to enhance stability and improve functional outcomes. Synthetic mesh or tendon grafts were used to augment reattachment where necessary.
5. Wound Closure: The wound was copiously irrigated. Two large bore suction drains were placed deep to the muscle fascia. Fascia and subcutaneous layers were closed in layers with absorbable sutures, and the skin was closed with staples.

Concomitant Pulmonary Wedge Resection

Simultaneously, a thoracic surgical team performed a video-assisted thoracoscopic surgery (VATS) wedge resection of the solitary right lower lobe pulmonary nodule. This was deemed appropriate given the solitary nature and size, aiming for complete surgical removal of all macroscopic disease.

Post-Operative Protocol & Rehabilitation

Immediate Post-Operative Period

• Pain Management: Aggressive multimodal analgesia regimen, including epidural analgesia or continuous nerve blocks, opioid patient-controlled analgesia (PCA), and NSAIDs, was utilized.
• Wound Care: Daily wound checks for signs of infection or hematoma. Drains were monitored and removed when output decreased appropriately (typically 48-72 hours).
• DVT Prophylaxis: Pharmacological (low molecular weight heparin) and mechanical (intermittent pneumatic compression devices) prophylaxis for DVT was initiated immediately and continued until full mobilization.
• Antibiotics: Prophylactic broad-spectrum antibiotics were continued for 48-72 hours post-operatively.

Rehabilitation

• Day 1 Post-op: Passive and active-assisted range of motion exercises for the hip and knee were initiated. Quadriceps and gluteal isometric exercises.
• Day 2-3 Post-op: Out-of-bed mobilization with an assistive device (walker or crutches) was started. Partial weight-bearing (25% body weight) was permitted on the operative limb, gradually progressing to full weight-bearing over 4-6 weeks as tolerated and guided by the physical therapy team. This early mobilization is crucial for endoprosthetic reconstructions to prevent stiffness and muscle atrophy.
• Weeks 2-6: Progressive strengthening exercises for the hip and knee musculature. Gradual increase in weight-bearing and gait training. Emphasis on balance and proprioception.
• Months 3-6: Advanced strengthening, functional training, and sport-specific rehabilitation, avoiding high-impact activities initially.
• Long-term: Lifelong follow-up with the orthopedic oncology team is essential.

Adjuvant Therapy

Following recovery from surgery and wound healing, the patient resumed the remaining cycles of adjuvant chemotherapy (totaling approximately 10 months of chemotherapy). The specifics of the adjuvant regimen were determined by the pediatric oncology team based on the definitive pathology report (tumor necrosis percentage, margin status) and the patient's overall response. Given the metastatic disease at presentation, the patient also received consolidation radiation therapy to the primary tumor site post-operatively (if margins were marginal or for high risk of recurrence, though not typically necessary with wide surgical margins and good chemotherapy response). The lung nodule was completely resected, and no further radiation was planned for the lung unless recurrence was noted.

Surveillance Protocol

Aggressive surveillance is critical for Ewing Sarcoma due to the high risk of local recurrence and distant metastasis.
* Clinical Examination: Every 3 months for the first 2 years, then every 6 months for years 3-5, and annually thereafter.
* Imaging:
* Plain radiographs of the reconstructed femur: Every 3 months for the first year, then every 6 months for years 2-5, and annually thereafter, to monitor for implant stability, aseptic loosening, and periprosthetic lucencies.
* CT chest: Every 3 months for the first 2 years, then every 6 months for years 3-5, to screen for pulmonary metastases.
* MRI of the primary site: Annually for 5 years to screen for local recurrence.
* PET-CT or bone scan: Annually for 3-5 years, depending on risk stratification and initial disease extent.
* Laboratory: Regular blood tests including CBC, ESR, CRP, and LDH.

Potential Complications

• Local Recurrence: Despite wide margins, recurrence can occur, especially with poor response to chemotherapy or positive microscopic margins.
• Distant Metastasis: Lungs, other bones, and bone marrow are common sites.
• Infection: Peri-prosthetic infection is a devastating complication, requiring prolonged antibiotics, debridement, and potentially implant removal.
• Aseptic Loosening: Mechanical failure of the implant-bone interface.
• Periprosthetic Fracture: Fracture around the prosthetic stem.
• Non-union: If an allograft was used for reconstruction.
• Vascular or Neurological Injury: Intraoperative or post-operative.
• Limb Length Discrepancy: If growth plate was affected or inadequate reconstruction.
• Functional Limitations: Persistent pain, weakness, or range of motion restrictions.

Pearls & Pitfalls (Crucial for FRCS/Board Exams)

Pearls

• Biopsy is Paramount: A properly planned, image-guided core needle biopsy performed by an orthopedic oncologist, including the entire tract within the planned definitive resection, is non-negotiable . Inadequate or inappropriately placed biopsies can compromise subsequent limb salvage attempts or local control.
• Multidisciplinary Team Approach: Ewing Sarcoma management is complex and requires seamless collaboration between orthopedic oncology, pediatric oncology, radiation oncology, pathology, and radiology. This is not a surgeon-only disease.
• Neoadjuvant Chemotherapy is Standard: Always administer neoadjuvant chemotherapy before definitive local control. It addresses micrometastatic disease, improves survival, and often shrinks the primary tumor, facilitating a safer and more effective surgical resection with wider margins.
• Achieve Wide Surgical Margins: The goal for resectable Ewing Sarcoma is an en bloc resection with histologically negative wide margins (defined as >1 cm of normal tissue beyond the tumor pseudocapsule) to minimize local recurrence risk. This may necessitate sacrifice of adjacent structures.
• Aggressive Staging and Surveillance: Ewing Sarcoma is highly metastatic. Thorough initial staging (CT chest, PET-CT/bone scan, bone marrow biopsy if indicated) is crucial. Lifelong follow-up with regular imaging is essential for early detection of recurrence or metastasis.
• Prognostic Indicators: Presence of metastasis at diagnosis, large tumor volume (>200 ml), poor histological response to neoadjuvant chemotherapy (<50% tumor necrosis), and elevated LDH are all associated with a worse prognosis.
• Reconstruction Choices: For large diaphyseal defects in adolescents/young adults, modular endoprostheses offer immediate stability and facilitate early rehabilitation, often preferred over biological options like allografts which have higher rates of non-union and fracture.
• Systemic Disease: Always remember Ewing Sarcoma is a systemic disease. Local control, however effective, is insufficient without systemic chemotherapy.

Pitfalls

• Inadequate Biopsy: A biopsy that is either insufficient for diagnosis, takes an inappropriate tract (e.g., through an unaffected muscle compartment), or leads to contamination of neurovascular bundles can jeopardize limb salvage and increase local recurrence risk.
• Delay in Diagnosis: Prolonged symptoms without aggressive workup can lead to increased tumor burden, higher metastatic rates, and worse prognosis.
• Incomplete Staging: Missing distant metastases (e.g., bone marrow, other bones, or occult lung nodules) can lead to undertreatment and poorer outcomes.
• Inadequate Surgical Margins: Operating without pre-operative chemotherapy or failing to achieve wide margins significantly increases the risk of local recurrence, often necessitating further surgery or radiation.
• Over-reliance on Radiation Monotherapy: While effective for local control in some unresectable cases, radiation alone for resectable Ewing Sarcoma is generally inferior to surgery for achieving durable local control and has its own long-term complications (secondary malignancy, fibrosis, growth disturbance).
• Ignoring Constitutional Symptoms: Fever, weight loss, and fatigue in an adolescent with bone pain should immediately raise suspicion for malignancy and prompt an urgent workup.
• Peri-prosthetic Infection: A catastrophic complication in endoprosthetic reconstruction. Meticulous surgical technique, strict sterile protocols, and appropriate prophylactic antibiotics are crucial. Any suspicion warrants aggressive investigation and management.
• Failure to Collaborate: Not engaging the full multidisciplinary team from the outset can lead to suboptimal treatment plans and compromised patient outcomes.